New agents and devices offer promise to control IOP and slow, perhaps even stop, the advancing vision loss that is common in glaucoma. Research and development to restore vision is starting to show significant results in preclinical models and early stage clinical trials.
Dry eye is common in patients with glaucoma and often presumed to be related to the preservative in IOP-lowering medications. Considering alternate causes should also be weighed, in addition to a variety of management techniques.
Not long ago, a colleague asked me if I performed Goldmann tonometry on all of my glaucoma patients. Without hesitation I said, “No.” When asked why not, I simply answered that not all of my patients are physically able to have the test performed on them.
A unique, third-generation Flying Eye Hospital is giving wings to Orbis' mission to prevent blindness worldwide. The hospital is the world’s only mobile ophthalmic teaching hospital located on an MD-10 aircraft, and is the byproduct of six years of work by experts in aviation and hospital engineering.
NASA’s Vision Impairment and Intracranial Pressure (VIIP) project was started after NASA realized many astronauts return from space with vision problems, and these problems may last for years after mission completion.
With the advent of electronic health records, it is now easier than ever to keep up with what medications a patient is actually taking, and (especially in the arena of glaucoma) the several classes of medications, such as steroids, beta blockers, and antihistamines, that can influence how patients’ eyes behave. With this in mind, I had a patient come in the other day with an interesting question regarding her intraocular pressure (IOP).
It’s been a busy week for ophthalmology research and news after both the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle and the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in New Orleans.